Physician profile
Debra L Geiger
NPI 1811081722
$2,936.80
in general payments reported to CMS, 2019-2025
30 companies · $288 in 2025
The $288 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $370 · 2020: $292 · 2021: $390 · 2022: $299 · 2023: $705 · 2024: $594 · 2025: $288.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,587.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,586.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $381.21 | 2019-2024 | Wegovy, Rybelsus, Ozempic |
| Astrazeneca Pharmaceuticals Lp | $339.06 | 2019-2025 | Farxiga, Airsupra |
| Pfizer INC. | $304.18 | 2021-2025 | |
| Abbvie INC. | $270.03 | 2019-2023 | |
| Lilly USA, LLC | $207.67 | 2019-2025 | Jardiance, Mounjaro, Emgality |
| Amgen INC. | $185.44 | 2019-2025 | Otezla, Repatha, Repatha |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $152.09 | 2019-2023 | Xifaxan |
| Exact Sciences Corporation | $135.50 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Biocryst US Sales Co., LLC | $127.49 | 2024 | Orladeyo |
| Shield Therapeutics INC | $99.71 | 2023-2025 | Accrufer |
| Glaxosmithkline, LLC. | $85.04 | 2022-2023 | Shingrix, Arexvy |
| Amarin Pharma, INC. | $79.35 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $69.28 | 2021-2024 | Jardiance |
| Astellas Pharma US INC | $68.18 | 2023-2024 | Veozah |
| Sanofi Pasteur INC. | $50.09 | 2022-2023 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceuticals, INC. | $45.87 | 2020-2021 | |
| Janssen Pharmaceuticals, INC | $41.99 | 2019 | |
| Esperion Therapeutics, INC. | $41.58 | 2024 | Nexletol |
| Eisai INC. | $36.70 | 2020 | |
| Otsuka America Pharmaceutical, INC. | $28.23 | 2023 | Rexulti |
| Takeda Pharmaceuticals U.S.A., INC. | $26.84 | 2019-2021 | |
| Inspire Medical Systems, INC. | $25.12 | 2023 | Inspire |
| Ibsa Pharma INC. | $24.37 | 2019 | |
| Seqirus USA INC | $20.97 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $18.48 | 2021 | |
| Phathom Pharmaceuticals, INC. | $18.46 | 2024 | Voquezna |
| Idorsia Pharmaceuticals US INC | $17.53 | 2023 | Quviviq |
| Kowa Pharmaceuticals America, INC. | $13.91 | 2020 | |
| Allergan, INC. | $11.35 | 2020 | |
| Merck Sharp & Dohme LLC | $11.08 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Debra Geiger listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.